<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210505</url>
  </required_header>
  <id_info>
    <org_study_id>Pending</org_study_id>
    <secondary_id>1R01HS026724</secondary_id>
    <nct_id>NCT04210505</nct_id>
  </id_info>
  <brief_title>Nasal Decolonization of Dialysis Patients Noses</brief_title>
  <acronym>PAINTS</acronym>
  <official_title>Povidone-iodine to Stop Access-related Infections and Transmission of Staphylococcus Aureus (PAINTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marin L. Schweizer, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agency for Healthcare Research and Quality (AHRQ)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemodialysis patients are at high-risk for infections, specifically Staphylococcus aureus
      infections. The investigators propose to 1) implement a novel intervention (nasal
      povidone-iodine at each hemodialysis session) to prevent S. aureus infections using a
      stepped-wedge cluster randomized trial, and 2) evaluate the feasibility and acceptability of
      this intervention. If successful, this intervention can be used among hemodialysis patients,
      and evaluated in other high-risk patient populations to prevent S. aureus infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PAINTS study is a stepped-wedge cluster randomized trial that will compare standard care
      to an intervention that includes nasal povidone-iodine at each hemodialysis session to
      determine whether nasal povidone-iodine prevents infections. The nasal povidone-iodine will
      be donated by 3M. This formulation of nasal povidone-iodine was developed under the Tentative
      Final Monograph for Health-Care Antiseptic Drug Products 21 CFR Parts 333 and 369 (Docket #
      75N-183H), Federal Register Volume 59, Number 116, Friday, June 17, 1994, Proposed Rules.
      However, the product need not be controlled like a pharmaceutical drug. The product may be
      stored and controlled similarly to an iodine or alcohol skin preparation product.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Staphylococcus aureus bloodstream infection</measure>
    <time_frame>Through study completion (up to 3 years)</time_frame>
    <description>Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definition: a Staphylococcus aureus positive blood specimen collected in the outpatient setting or within 1 calendar day after a hospital admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Staphylococcus aureus access related bloodstream infection (ARBSI)</measure>
    <time_frame>Through study completion (up to 3 years)</time_frame>
    <description>Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definition: a Staphylococcus aureus bloodstream infection with the suspected source reported as the vascular access or uncertain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Staphylococcus aureus local access site infection</measure>
    <time_frame>Through study completion (up to 3 years)</time_frame>
    <description>Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definition: pus, redness or increased swelling at the vascular access site when an ARBSI is not present but with positive culture for Staphylococcus aureus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Bloodstream infections by any pathogen</measure>
    <time_frame>Through study completion (up to 3 years)</time_frame>
    <description>Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network definition: a positive blood specimen collected in the outpatient setting or within 1 calendar day after a hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Access related bloodstream infection by any pathogen</measure>
    <time_frame>Through study completion (up to 3 years)</time_frame>
    <description>Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network definition: a bloodstream infection with the suspected source reported as the vascular access or uncertain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Local access site infection</measure>
    <time_frame>Through study completion (up to 3 years)</time_frame>
    <description>Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) definition: pus, redness or increased swelling at the vascular access site when an ARBSI is not present</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1825</enrollment>
  <condition>Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Nasal Povidone-Iodine Decolonization Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal povidone-iodine (3M Skin and Nasal Antiseptic) will be applied to the patients' noses at each hemodialysis session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care. This will be usual care at each hemodialysis center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-Iodine Topical Ointment</intervention_name>
    <description>Intranasal povidone-iodine will be applied to the lower anterior nares (i.e. nostril) of patients undergoing hemodialysis before each session.</description>
    <arm_group_label>Nasal Povidone-Iodine Decolonization Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Control group will receive standard care as provided by the dialysis center</description>
    <arm_group_label>Nasal Povidone-Iodine Decolonization Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients receiving outpatient chronic hemodialysis at one of the 16 study
             dialysis centers.

        Note: the unit of randomization is the dialysis center, not the individual patient

        Exclusion Criteria:

        Patients receiving peritoneal dialysis or home hemodialysis Pregnant women Patients with
        known sensitivity or allergy to iodine (documented or verbalized) Patients with active
        bacterial infections Children &lt; 18 years of age. Patients with infections at the beginning
        of the study will enter the study after antibiotic treatment is complete.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marin L Schweizer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marin L Schweizer, PhD</last_name>
    <phone>319-338-0581</phone>
    <phone_ext>3831</phone_ext>
    <email>marin-schweizer@uiowa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Marin L Schweizer</last_name>
      <phone>319-338-0581</phone>
      <phone_ext>3193380581</phone_ext>
      <email>marin-schweizer@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Marin L. Schweizer, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>povidone-iodine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators will submit an electronic version of each peer-reviewed accepted manuscript to PubMed Central to be made publicly available within 12 months of publication. The investigators will respond to requests for restricted public health data sets and ensure responses follow appropriate processes, documentation, and approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Until year 2025</ipd_time_frame>
    <ipd_access_criteria>Upon request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

